The original GHK-Cu research: what Pickart actually found
A 1970s discovery that quietly built a research base most people are only now hearing about.
TL;DR
- GHK-Cu was first isolated from human blood plasma in 1973 by Dr. Loren Pickart.
- The original observation: blood from younger donors helped older liver cells behave more like younger ones in culture.
- Decades of follow-up studies built the published research base on skin, hair, and tissue repair.
What it is
GHK-Cu (in plain English: a three-amino-acid peptide that binds a copper atom and circulates naturally in your blood) was identified by Dr. Loren Pickart in the early 1970s while he was studying why blood from younger donors seemed to “rejuvenate” liver cells in a dish. The active component turned out to be a tiny copper-binding tripeptide. That discovery launched the published research thread now cited across skin, wound, and hair literature (Pickart & Margolina, International Journal of Molecular Sciences, 2018).
How it works
Picture an emergency repair crew that already lives inside your body. Most of the time the crew works at a steady pace. When tissue is damaged, GHK-Cu acts like a dispatch radio — the molecule binds copper, signals to nearby cells, and helps coordinate the repair response. Pickart’s research described how the peptide influences fibroblasts (the skin cells that build collagen) and how plasma levels of GHK-Cu drop with age. The “dispatch radio gets quieter as you age” framing is a fair plain-English summary of his findings.
Who asks about it
People come to this topic when they see GHK-Cu cited as “the most studied copper peptide” or “discovered in the 1970s” and want to know whether the citation is accurate. It is. The renewed attention in 2026 builds on a research base that has been steady — not flashy — for decades.
What the research says
Pickart’s early publications described GHK-Cu’s role in attracting immune and repair cells to wounded tissue. Later studies tied the peptide to increased collagen synthesis and changes in gene expression in skin fibroblasts (Pickart et al., Biomed Research International, 2015). Most of the strongest data is from cell culture and animal models. Larger human trials with modern designs are limited, which is honest to acknowledge alongside the long publication history.
What to know before considering it
A long research history is not the same as proof of a specific outcome. Topical and injectable forms have different evidence bases. Compounded injectable GHK-Cu requires a licensed clinician evaluation and pharmacy preparation under 503A standards.
The Halftime POV
The Pickart research is a real, decades-deep base — not a viral marketing invention. Honest framing means acknowledging the depth of the literature and its limits. The peptide has earned the attention; the marketing claims still need to be checked against what the studies actually showed.
Related reading:
- GHK-Cu: the copper peptide and skin biology
- How GHK-Cu promotes collagen synthesis: the mechanism
- Collagen synthesis: what the peptide literature actually shows
FAQ
Q: Who discovered GHK-Cu? A: Dr. Loren Pickart isolated the GHK peptide from human plasma in the early 1970s. The copper-binding form, GHK-Cu, has been the focus of his published research ever since.
Q: Is GHK-Cu a new peptide? A: No. GHK-Cu has been studied for more than 50 years. The 2020s renewed interest is more about market attention than new biology.
Q: Is the original Pickart research credible? A: The early plasma-isolation and tissue-repair studies are peer-reviewed and reproducible. Many later claims marketed online go beyond what those studies actually showed.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
